文献速递结核与非结核分枝杆菌

加替沙星药效学指导的耐多药结核最优剂量

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究通过28天 Hollow-fiber 结核模型确定加替沙星最佳暴露目标为AUC0-24/MIC=184,蒙特卡洛模拟识别出肺MDR-TB 800 mg/日、脑膜MDR-TB 1200 mg/日的最佳剂量,并经两项前瞻性临床试验数据验证,药敏折点MIC≤0.5 mg/L。

要点

  • 肺MDR-TB推荐加替沙星800 mg/日,脑膜MDR-TB推荐1200 mg/日。
  • 最佳暴露目标为AUC0-24/MIC=184,药敏折点MIC≤0.5 mg/L。
  • MIC>2 mg/L时79%治疗失败,MIC≤0.5 mg/L时98%治愈。

核心结论

  • 加替沙星治疗肺MDR-TB推荐800 mg/日,治疗脑膜MDR-TB推荐1200 mg/日;≤400 mg/日剂量次优。
  • 加替沙星在MIC 0.5–2 mg/L区间为剂量依赖性敏感区。

研究设计与样本

  • 28天加替沙星 Hollow-fiber 结核模型研究,确定最佳杀灭率和耐药抑制的暴露目标。
  • 蒙特卡洛实验模拟10000例成人肺或脑膜MDR-TB患者,识别最佳剂量。
  • 利用两项前瞻性肺和脑膜结核临床试验数据,通过probit分析和CART分析验证剂量和药敏折点。

主要发现

  • Hollow-fiber 模型中与最佳杀灭率和耐药抑制相关的暴露目标为AUC0-24/MIC=184。
  • 蒙特卡洛实验识别肺MDR-TB最佳剂量800 mg/日,脑膜MDR-TB最佳剂量1200 mg/日,临床药敏折点MIC≤0.5 mg/L。
  • 临床试验CART分析显示MIC>2 mg/L时79%患者治疗失败,MIC≤0.5 mg/L时98%治愈。
  • Probit分析显示肺结核800 mg/日、脑膜结核1200 mg/日治疗时治愈概率>90%。

关键数值与推荐

  • 肺MDR-TB:加替沙星800 mg/日;脑膜MDR-TB:加替沙星1200 mg/日。
  • 最佳暴露目标:AUC0-24/MIC=184。
  • 药敏折点:MIC≤0.5 mg/L为敏感;MIC 0.5–2 mg/L为剂量依赖性敏感区。
  • MIC>2 mg/L时79%治疗失败;MIC≤0.5 mg/L时98%治愈。
  • ≤400 mg/日剂量次优。

临床怎么用

  • 临床治疗肺MDR-TB可考虑加替沙星800 mg/日,脑膜MDR-TB可考虑1200 mg/日。
  • 应根据MIC值评估疗效,MIC≤0.5 mg/L预期治愈率高,MIC>2 mg/L失败风险高。
  • 避免使用≤400 mg/日剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gatifloxacin is used for the treatment of multidrug-resistant tuberculosis (MDR-TB). The optimal dose is unknown. METHODS: We performed a 28-day gatifloxacin hollow-fiber system model of tuberculosis (HFS-TB) study in order to identify the target exposures associated with optimal kill rates and resistance suppression. Monte Carlo experiments (MCE) were used to identify the dose that would achieve the target exposure in 10000 adult patients with meningeal or pulmonary MDR-TB. The optimal doses identified were validated using probit analyses of clinical data from 2 prospective clinical trials of patients with pulmonary and meningeal tuberculosis. Classification and regression-tree (CART) analyses were used to identify the gatifloxacin minimum inhibitory concentration (MIC) below which patients failed or relapsed on combination therapy. RESULTS: The target exposure associated with optimal microbial kill rates and resistance suppression in the HFS-TB was a 0-24 hour area under the concentration-time curve-to-MIC of 184. MCE identified an optimal gatifloxacin dose of 800 mg/day for pulmonary and 1200 mg/day for meningeal MDR-TB, and a clinical susceptibility breakpoint of MIC ≤ 0.5 mg/L. In clinical trials, CART identified that 79% patients failed therapy if MIC was >2 mg/L, but 98% were cured if MIC was ≤0.5 mg/L. Probit analysis of clinical data demonstrated a >90% probability of a cure in patients if treated with 800 mg/day for pulmonary tuberculosis and 1200 mg/day for meningeal tuberculosis. Doses ≤400 mg/day were suboptimal. CONCLUSIONS: Gatifloxacin doses of 800 mg/day and 1200 mg/day are recommended for pulmonary and meningeal MDR-TB treatment, respectively. Gatifloxacin has a susceptible dose-dependent zone at MICs 0.5-2 mg/L.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Deshpande D, Pasipanodya JG, Srivastava S, et al. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. Clin Infect Dis. 2018. PMID: 30496459. doi:10.1093/cid/ciy618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。